Q2 2026 saw higher sales and EBITDA(A) driven by record production and strong demand in both packaging and tissue, despite rising raw material and logistics costs. Net debt declined slightly, and the outlook anticipates continued margin pressure from costs and macro uncertainty.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.